Omacetaxine

Phase 2Small molecule

CChemGenex Pharmaceuticals

Omacetaxine is one of 2 small molecule programs targeting MACE. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MACETerminated

MACEPhase 2

Terminated

Competition

Competitive Landscape

1 competitor in MACE

#DrugCompanyPhaseTrials

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 2

Omacetaxine

CChemGenex Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Active, not recruiting

MACE

NCT03564873

Clinical

Trials by Indication[1]

Myelodysplastic Syndrome3 trials

Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01272245·36 enrolled

Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02159872·48 enrolled

Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT02141477·2 enrolled

MACE2 trials

Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS

Active, not recruiting·UUniversity of Colorado, Denver·Phase 1/2·NCT03564873·28 enrolled

Omacetaxine for Consolidation and Maintenance

Terminated·EEmory University·Phase 2·NCT01873495·7 enrolled

Advanced1 trial

Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

Completed·CChemGenex Pharmaceuticals·Phase 1·NCT00675350·12 enrolled

Acute Myeloid Leukemia1 trial

Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)

Completed·UUniversity of Illinois at Chicago·Phase 1·NCT04926285·6 enrolled

Myelodysplastic Syndromes1 trial

A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)

Withdrawn·UUniversity of Florida·Phase 1/2·NCT02835794

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Omacetaxine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Omacetaxine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Omacetaxine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ChemGenex Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CChemGenex Pharmaceuticals

Omacetaxine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Myelodysplastic Syndrome3 trials

MACE2 trials

Advanced1 trial

Acute Myeloid Leukemia1 trial

Myelodysplastic Syndromes1 trial

References

Drug Info

Quick Facts

Related News